%A C Ding
%A J Li
%A X Zhang
%J Current Opinion in Investigational Drugs
%T Bertilimumab (Cambridge Antibody Technology Group)
%X Cambridge Antibody Technology (CAT) is developing
bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.
%N 11
%P 1213-1219
%V 5
%D 2004
%L epprod3608